Q1 2023 13F Holders as of 3/31/2023
-
Type / Class
-
Equity / Common Stock, $0.001 par value per share
-
Shares outstanding
-
50M
-
Number of holders
-
87
-
Total 13F shares, excl. options
-
33.7M
-
Shares change
-
-1.29M
-
Total reported value, excl. options
-
$265M
-
Value change
-
-$7.3M
-
Put/Call ratio
-
0
-
Number of buys
-
37
-
Number of sells
-
-48
-
Price
-
$7.86
Significant Holders of KalVista Pharmaceuticals, Inc. - Common Stock, $0.001 par value per share (KALV) as of Q1 2023
110 filings reported holding KALV - KalVista Pharmaceuticals, Inc. - Common Stock, $0.001 par value per share as of Q1 2023.
KalVista Pharmaceuticals, Inc. - Common Stock, $0.001 par value per share (KALV) has 87 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 33.7M shares
of 50M outstanding shares and own 67.43% of the company stock.
Largest 10 shareholders include TCG Crossover Management, LLC (3.4M shares), Frazier Life Sciences Management, L.P. (3.24M shares), VR Adviser, LLC (2.92M shares), TANG CAPITAL MANAGEMENT LLC (2.65M shares), SUVRETTA CAPITAL MANAGEMENT, LLC (1.98M shares), Boxer Capital, LLC (1.65M shares), GREAT POINT PARTNERS LLC (1.6M shares), VANGUARD GROUP INC (1.58M shares), BlackRock Inc. (1.56M shares), and Jefferies Financial Group Inc. (1.2M shares).
This table shows the top 87 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.